Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer

被引：3
|
作者：
Mizuno, Nobumasa
Yamao, Kenji
Komatsu, Yoshito
Munakata, Masaki
Ishiguro, Atsushi
Yamaguchi, Taketo
Ohkawa, Shinichi
Kida, Mitsuhiro
Ioka, Tatsuya
Takeda, Koji
Kudo, Toshihiro
Kitano, Masayuki
Iguchi, Haruo
Tsuji, Akihito
Ito, Tetsuhide
Tanaka, Masao
Furuse, Junji
Hamada, Chikuma
Sakata, Yuh
机构：
[1] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi 464, Japan
[2] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido, Japan
[3] Misawa City Hosp, Dept Med Oncol, Misawa, Japan
[4] Hirosaki Univ, Dept Med Oncol, Hirosaki, Aomori, Japan
[5] Chiba Canc Ctr, Div Gastroenterol, Chiba 2608717, Japan
[6] Kanagawa Canc Ctr Hosp, Hepatobiliary & Pancreat Oncol Div, Yokohama, Kanagawa, Japan
[7] Kitasato Univ, Sch Med, Dept Med, Sagamihara, Kanagawa 228, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Hepatobiliary & Pancreat Oncol, Osaka, Japan
[9] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[10] Kinki Univ, Dept Med Oncol, Osaka, Japan
[11] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osakasayama, Japan
[12] Natl Hosp Org, Shikoku Canc Ctr, Dept Gastroenterol, Matsuyama, Ehime, Japan
[13] Kochi Hlth Sci Ctr, Dept Med Oncol, Kochi, Japan
[14] Kyushu Univ, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan
[15] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan
[16] Kyorin Univ, Sch Med, Dept Internal Med, Mitaka, Tokyo 181, Japan
[17] Tokyo Univ Sci, Fac Engn, Tokyo 162, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
263
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Adjuvant chemotherapy of S-1 versus S-1 plus metformin for resected pancreatic cancer: A multicenter and randomized phase II trial.
    Narita, Masato
    Furukawa, Masayuki
    Sakamoto, Ichiro
    Itoh, Yutaka
    Nakano, Hiroshi
    Naka, Takuji
    Sudo, Takeshi
    Yahara, Noboru
    Aoki, Hideki
    Oota, Kouji
    Matsumoto, Toshifumi
    Shimokawa, Mototsugu
    Hisano, Terumasa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [22] A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
    Pijnappel, Esther
    de Vos-Geelen, Judith
    Macarulla Mercade, Teresa
    Melisi, Davide
    Pfeiffer, Per
    Prager, Gerald W.
    Van Laarhoven, Hanneke W. M.
    Wilmink, Johanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
    Zhong, Sheng
    Qie, Shuai
    Yang, Liu
    Yan, Qi
    Ge, Linna
    Wang, Zhongfeng
    MEDICINE, 2017, 96 (30)
  • [24] A phase I study of IRISOX (irinotecan/S-1/oxaliplatin) in the second-line treatment for gemcitabine-refractory pancreatic cancer
    Miyata, E.
    Okuwaki, K.
    Imaizumi, H.
    Kida, M.
    Iwai, T.
    Yamauchi, H.
    Kaneko, T.
    Hasegawa, R.
    Adachi, K.
    Tadehara, M.
    Koizumi, W.
    ANNALS OF ONCOLOGY, 2018, 29
  • [25] A randomized phase II trial of adjuvant chemotherapy with S-1 versus S-1 and gemcitabine (GS) versus gemcitabine alone (GEM) in patients with resected pancreatic cancer (CAP-002 study).
    Yoshitomi, Hideyuki
    Shimizu, Hiroaki
    Yoshidome, Hiroyuki
    Ohtsuka, Masayuki
    Kato, Atsushi
    Furukawa, Katsunori
    Takayashiki, Tsukasa
    Kuboki, Satoshi
    Okamura, Daiki
    Suzuki, Daisuke
    Nakajima, Masayuki
    Aida, Toshiaki
    Miyazaki, Masaru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)
    Toyama, Hirochika
    Sugiura, Teiichi
    Fukutomi, Akira
    Asakura, Hirofumi
    Takeda, Yuriko
    Yamamoto, Kouji
    Hirano, Satoshi
    Satoi, Sohei
    Matsumoto, Ippei
    Takahashi, Shinichiro
    Morinaga, Soichiro
    Yoshida, Makoto
    Sakuma, Yasunaru
    Iwamoto, Hidetaka
    Shimizu, Yasuhiro
    Uesaka, Katsuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [27] Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)
    Sugiura, Teiichi
    Toyama, Hirochika
    Fukutomi, Akira
    Asakura, Hirofumi
    Takeda, Yuriko
    Yamamoto, Kouji
    Hirano, Satoshi
    Satoi, Sohei
    Matsumoto, Ippei
    Takahashi, Shinichiro
    Morinaga, Soichiro
    Yoshida, Makoto
    Sakuma, Yasunaru
    Iwamoto, Hidetaka
    Shimizu, Yasuhiro
    Uesaka, Katsuhiko
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2023, 30 (11) : 1249 - 1260
  • [28] A phase II multicentric trial of combined chemotherapy with gemcitabine plus S-1 in patients with advanced pancreatic cancer
    Ohkawa, S.
    Amano, A.
    Ueno, M.
    Miyakawa, K.
    Sugimori, K.
    Tanaka, K.
    Kida, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] Phase II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients
    Morizane, C.
    Okusaka, T.
    Ikeda, M.
    Furuse, J.
    Ohkawa, S.
    Nakachi, K.
    Suzuki, E.
    Ueno, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 388 - 388
  • [30] Randomized Phase II Trial of S-1 plus Irinotecan Versus S-1 plus Paclitaxel as First-line Treatment for Advanced Gastric Cancer (OGSG0402)
    Sugimoto, Naotoshi
    Fujitani, Kazumasa
    Imamura, Hiroshi
    Uedo, Noriya
    Iijima, Shohei
    Imano, Motohiro
    Shimokawa, Toshio
    Kurokawa, Yukinori
    Furukawa, Hiroshi
    Goto, Masahiro
    ANTICANCER RESEARCH, 2014, 34 (02) : 851 - 857
12345